ArticlePloS one2019
ACO: Time to move from the description of different phenotypes to the treatable traits.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Withdrawal of inhaled corticosteroids from patients with COPD with mild or moderate airflow limitation in primary care: a feasibility randomised trial.BMJ open respiratory research · 2022Trial
- Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?Frontiers in immunology · 2026Review
- Clinical characteristics of asthma-chronic obstructive pulmonary disease overlap phenotypes.Postepy dermatologii i alergologii · 2025Article
- A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study.The World Allergy Organization journal · 2023Article
- COPD Patients with Asthma Features in Vietnam: Prevalence and Suitability for Personalized Medicine.Journal of personalized medicine · 2023Article
- Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine.Journal of personalized medicine · 2023Review
- Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.Frontiers in immunology · 2023Article
- Type 2 inflammation in asthma and other airway diseases.ERJ open research · 2022Review
- Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.Postepy dermatologii i alergologii · 2022Article
- Chronic Obstructive Pulmonary Disease With Asthma-Like Features in the General Population in China.Frontiers in medicine · 2022Article
- ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour.Diagnostics (Basel, Switzerland) · 2021Review
- Asthma-COPD overlap: current understanding and the utility of experimental models.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Work absence in patients with asthma and/or COPD: a population-based study.NPJ primary care respiratory medicine · 2021Observational
- Update on Asthma-COPD Overlap (ACO): A Narrative Review.International journal of chronic obstructive pulmonary disease · 2021Review
- GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap.International journal of chronic obstructive pulmonary disease · 2021Review
- The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians.Journal of clinical medicine · 2020Review
- Prevalence of Seasonal Influenza Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Balearic Islands (Spain) and Its Effect on COPD Exacerbations: A Population-Based Retrospective Cohort Study.International journal of environmental research and public health · 2020Article
- Associations among chronic obstructive pulmonary disease with asthma, pneumonia, and corticosteroid use in the general population.PloS one · 2020Observational
- The Value of Inflammatory Biomarkers in Differentiating Asthma-COPD Overlap from COPD.International journal of chronic obstructive pulmonary disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count ≥300 cells/μL. The aim of this study was to compare the different phenotypes inside the ACO definition in a real-life population cohort.
methodsWe analyzed patients from the MAJORICA cohort who had a diagnosis of asthma and/or COPD based on current guidelines, laboratory data in 2014 and follow-up until 2015. Prevalence of ACO according to the different criteria, demographic, clinical and functional characteristics, prescriptions and use of health resources data were compared between three groups.
resultsWe included 603 patients. Prevalence of smoking asthmatics was 14%, COPD patients with high bronchodilator response 1.5% and eosinophilic COPD patients 12%. Smoking asthmatics were younger and used more rescue inhalers, corticosteroids and health resources. Conversely, eosinophilic COPD patients were older than the other groups, often treated with corticosteroids and had lower use of health resources. Most of the COPD patients with high bronchodilator response were included in the eosinophilic COPD group.
conclusionsACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of ≥300 blood eosinophils/μL as a treatable trait should be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.